Data from treatment trials in systemic sclerosis support the use of immunosuppressive therapy, with the treatment benefit largely relating to the prevention of progression of lung disease. PubMed, Nat Rev Rheumatol, 2014 Sep 30. (Also see: Pulmonary Fibrosis Treatments and Connective Tissue Disease)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.